^
No biomarker
Triple Negative Breast Cancer
sacituzumab govitecan-hziy
Sensitive: A1 - Approval
Gilead Press Release - 4 weeks
PD-L1 expression
Triple Negative Breast Cancer
atezolizumab
Sensitive: A1 - Approval
PD-L1 expression
Triple Negative Breast Cancer
pembrolizumab
Sensitive: A1 - Approval
No biomarker
Triple Negative Breast Cancer
pembrolizumab
Sensitive: A1 - Approval
No biomarker
Triple Negative Breast Cancer
CaT
Sensitive: A2 - Guideline
BRCA2 mutation
Triple Negative Breast Cancer
cisplatin
Sensitive: A2 - Guideline
BRCA1 mutation
Triple Negative Breast Cancer
cisplatin
Sensitive: A2 - Guideline
BRCA2 mutation
Triple Negative Breast Cancer
carboplatin
Sensitive: A2 - Guideline
BRCA1 mutation
Triple Negative Breast Cancer
carboplatin
Sensitive: A2 - Guideline
BRCA2 mutation
Triple Negative Breast Cancer
gemcitabine
Sensitive: A2 - Guideline
BRCA1 mutation
Triple Negative Breast Cancer
gemcitabine
Sensitive: A2 - Guideline
BRCA2 mutation
Triple Negative Breast Cancer
capecitabine
Sensitive: A2 - Guideline
BRCA1 mutation
Triple Negative Breast Cancer
capecitabine
Sensitive: A2 - Guideline
BRCA2 mutation
Triple Negative Breast Cancer
vinorelbine tartrate
Sensitive: A2 - Guideline
BRCA1 mutation
Triple Negative Breast Cancer
vinorelbine tartrate
Sensitive: A2 - Guideline
BRCA2 mutation
Triple Negative Breast Cancer
eribulin mesylate
Sensitive: A2 - Guideline
BRCA1 mutation
Triple Negative Breast Cancer
eribulin mesylate
Sensitive: A2 - Guideline
BRCA2 mutation
Triple Negative Breast Cancer
pegylated liposomal doxorubicin
Sensitive: A2 - Guideline
BRCA1 mutation
Triple Negative Breast Cancer
pegylated liposomal doxorubicin
Sensitive: A2 - Guideline
BRCA2 mutation
Triple Negative Breast Cancer
paclitaxel
Sensitive: A2 - Guideline
BRCA2 mutation
Triple Negative Breast Cancer
olaparib
Sensitive: A2 - Guideline
BRCA1 mutation
Triple Negative Breast Cancer
olaparib
Sensitive: A2 - Guideline
BRCA2 mutation
Triple Negative Breast Cancer
talazoparib
Sensitive: A2 - Guideline
BRCA1 mutation
Triple Negative Breast Cancer
talazoparib
Sensitive: A2 - Guideline
No biomarker
Triple Negative Breast Cancer
carboplatin
Sensitive: A2 - Guideline
BRCA2 mutation
Triple Negative Breast Cancer
PARP inhibitor
Sensitive: A2 - Guideline
BRCA1 mutation
Triple Negative Breast Cancer
PARP inhibitor
Sensitive: A2 - Guideline
BRCA2 mutation
Triple Negative Breast Cancer
doxorubicin hydrochloride
Sensitive: A2 - Guideline
BRCA1 mutation
Triple Negative Breast Cancer
doxorubicin hydrochloride
Sensitive: A2 - Guideline
BRCA1 mutation
Triple Negative Breast Cancer
paclitaxel
Sensitive: A2 - Guideline
PD-L1 expression
Triple Negative Breast Cancer
Immunotherapy
Sensitive: A2 - Guideline
BRCA1 mutation
Triple Negative Breast Cancer
CaT
Sensitive: B - Late Trials
No biomarker
Triple Negative Breast Cancer
IPI-549
Sensitive: B - Late Trials
AKT1 mutation
Triple Negative Breast Cancer
GDC-0068
Sensitive: B - Late Trials
PTEN mutation
Triple Negative Breast Cancer
GDC-0068
Sensitive: B - Late Trials
PD-L1 overexpression
Triple Negative Breast Cancer
pembrolizumab
Sensitive: B - Late Trials
PIK3CA mutation
Triple Negative Breast Cancer
GDC-0068
Sensitive: B - Late Trials
BRCA2 mutation
Triple Negative Breast Cancer
carboplatin + paclitaxel
Sensitive: B - Late Trials
BRCA2 mutation
Triple Negative Breast Cancer
ABT-888
Sensitive: B - Late Trials
BRCA1 mutation
Triple Negative Breast Cancer
ABT-888
Sensitive: B - Late Trials
CDKN2B mutation
Triple Negative Breast Cancer
atezolizumab
Sensitive: B - Late Trials
CDKN2A mutation
Triple Negative Breast Cancer
atezolizumab
Sensitive: B - Late Trials
BRCA2 mutation
Triple Negative Breast Cancer
atezolizumab
Sensitive: B - Late Trials
BRCA1 mutation
Triple Negative Breast Cancer
atezolizumab
Sensitive: B - Late Trials
ER positive + HER-2 negative
Triple Negative Breast Cancer
cyclophosphamide oral + thiotepa
Sensitive: B - Late Trials
TMB-H + PD-L1 expression
Triple Negative Breast Cancer
atezolizumab
Sensitive: B - Late Trials
No biomarker
Triple Negative Breast Cancer
trilaciclib
Sensitive: B - Late Trials
No biomarker
Triple Negative Breast Cancer
CT7001
Sensitive: B - Late Trials
HR positive
Triple Negative Breast Cancer
olaparib
Sensitive: C1 - Off-label
HRD
Triple Negative Breast Cancer
olaparib
Sensitive: C1 - Off-label
BRCA2 mutation
Triple Negative Breast Cancer
niraparib
Sensitive: C1 - Off-label
BRCA1 mutation
Triple Negative Breast Cancer
niraparib
Sensitive: C1 - Off-label
TMB-H
Triple Negative Breast Cancer
pembrolizumab
Sensitive: C1 - Off-label
BRCA1 mutation
Triple Negative Breast Cancer
rucaparib
Sensitive: C1 - Off-label
PD-L1 expression
Triple Negative Breast Cancer
durvalumab
Sensitive: C1 - Off-label
BRCA2 mutation
Triple Negative Breast Cancer
pamiparib
Sensitive: C1 - Off-label
BRCA1 mutation
Triple Negative Breast Cancer
pamiparib
Sensitive: C1 - Off-label
BRCA1 mutation
Triple Negative Breast Cancer
tislelizumab + pamiparib
Sensitive: C2 – Inclusion Criteria
PTEN-L
Triple Negative Breast Cancer
GDC-0068
Sensitive: C2 – Inclusion Criteria
AR positive
Triple Negative Breast Cancer
enzalutamide
Sensitive: C2 – Inclusion Criteria
PD-L1 expression
Triple Negative Breast Cancer
avelumab
Sensitive: C2 – Inclusion Criteria
PD-L1 expression
Triple Negative Breast Cancer
olaparib + durvalumab + cediranib
Sensitive: C2 – Inclusion Criteria
BRCA1 mutation
Triple Negative Breast Cancer
olaparib + durvalumab
Sensitive: C2 – Inclusion Criteria
HRD
Triple Negative Breast Cancer
tislelizumab
Sensitive: C2 – Inclusion Criteria
BRCA2 mutation
Triple Negative Breast Cancer
tislelizumab
Sensitive: C2 – Inclusion Criteria
BRCA2 mutation
Triple Negative Breast Cancer
durvalumab
Sensitive: C2 – Inclusion Criteria
PD-L1 expression
Triple Negative Breast Cancer
toripalimab
Sensitive: C2 – Inclusion Criteria
TLE3 expression
Triple Negative Breast Cancer
eribulin mesylate
Sensitive: C3 – Early Trials
AKT1 amplification
Triple Negative Breast Cancer
BKM120
Sensitive: C3 – Early Trials
AKT1 E17K
Triple Negative Breast Cancer
BKM120
Sensitive: C3 – Early Trials
PIK3CA mutation
Triple Negative Breast Cancer
everolimus
Sensitive: C3 – Early Trials
PALB2 mutation
Triple Negative Breast Cancer
everolimus
Sensitive: C3 – Early Trials
BRCA2 mutation
Triple Negative Breast Cancer
gemcitabine + eribulin mesylate
Resistant: C3 – Early Trials
BRCA1 mutation
Triple Negative Breast Cancer
gemcitabine + eribulin mesylate
Resistant: C3 – Early Trials
AR positive
Triple Negative Breast Cancer
palbociclib
Sensitive: C3 – Early Trials
CD47 overexpression
Triple Negative Breast Cancer
VT1021
Sensitive: C3 – Early Trials
BRCA1 mutation
Triple Negative Breast Cancer
pembrolizumab + niraparib
Sensitive: C3 – Early Trials
BRCA2 mutation
Triple Negative Breast Cancer
pembrolizumab + niraparib
Sensitive: C3 – Early Trials
PD-L1 underexpression
Triple Negative Breast Cancer
atezolizumab + RG6180
Sensitive: C3 – Early Trials
PTEN mutation
Triple Negative Breast Cancer
pembrolizumab
Resistant: C3 – Early Trials
PTEN mutation
Triple Negative Breast Cancer
atezolizumab
Resistant: C3 – Early Trials
TMB-H
Triple Negative Breast Cancer
atezolizumab
Sensitive: C3 – Early Trials
PD-L1 overexpression
Triple Negative Breast Cancer
olaparib
Sensitive: C3 – Early Trials
FOXA1 overexpression
Triple Negative Breast Cancer
carboplatin + docetaxel
Resistant: C3 – Early Trials
AR overexpression
Triple Negative Breast Cancer
TAK 700
Sensitive: C3 – Early Trials
CD8-H
Triple Negative Breast Cancer
pembrolizumab
Sensitive: C3 – Early Trials
MYC amplification
Triple Negative Breast Cancer
talazoparib
Resistant: C3 – Early Trials
CD36 overexpression
Triple Negative Breast Cancer
VT1021
Sensitive: C3 – Early Trials
AR positive
Triple Negative Breast Cancer
pembrolizumab
Sensitive: C3 – Early Trials
MMP17 expression + EGFR expression + RB1 expression
Triple Negative Breast Cancer
erlotinib + palbociclib
Sensitive: C3 – Early Trials
MMP17 expression + EGFR expression + RB1 expression
Triple Negative Breast Cancer
erlotinib
Resistant: C3 – Early Trials
PD-L1 expression + CD68 positive
Triple Negative Breast Cancer
durvalumab
Sensitive: C3 – Early Trials
PD-L1 amplification
Triple Negative Breast Cancer
durvalumab
Sensitive: C3 – Early Trials